eDreams ODIGEO S.A. (EDEMY) Stock Competitors & Peer Comparison

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 423.2M. In comparison, TRPCF has a market cap of 32.3B. Regarding current trading prices, EDEMY is priced at $40.00, while TRPCF trades at $50.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 7.63, whereas TRPCF's P/E ratio is 7.11. In terms of profitability, EDEMY's ROE is +0.21%, compared to TRPCF's ROE of +0.20%. Regarding short-term risk, EDEMY is less volatile compared to TRPCF. This indicates potentially lower risk in terms of short-term price fluctuations for EDEMY.Check TRPCF's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 423.2M. In comparison, AMADF has a market cap of 26.6B. Regarding current trading prices, EDEMY is priced at $40.00, while AMADF trades at $61.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 7.63, whereas AMADF's P/E ratio is 17.36. In terms of profitability, EDEMY's ROE is +0.21%, compared to AMADF's ROE of +0.27%. Regarding short-term risk, EDEMY is less volatile compared to AMADF. This indicates potentially lower risk in terms of short-term price fluctuations for EDEMY.Check AMADF's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 423.2M. In comparison, AMADY has a market cap of 26.6B. Regarding current trading prices, EDEMY is priced at $40.00, while AMADY trades at $61.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 7.63, whereas AMADY's P/E ratio is 17.40. In terms of profitability, EDEMY's ROE is +0.21%, compared to AMADY's ROE of +0.27%. Regarding short-term risk, EDEMY is less volatile compared to AMADY. This indicates potentially lower risk in terms of short-term price fluctuations for EDEMY.Check AMADY's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 423.2M. In comparison, TNGCF has a market cap of 6.6B. Regarding current trading prices, EDEMY is priced at $40.00, while TNGCF trades at $2.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 7.63, whereas TNGCF's P/E ratio is 18.67. In terms of profitability, EDEMY's ROE is +0.21%, compared to TNGCF's ROE of N/A. Regarding short-term risk, EDEMY is more volatile compared to TNGCF. This indicates potentially higher risk in terms of short-term price fluctuations for EDEMY.Check TNGCF's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 423.2M. In comparison, TUIFF has a market cap of 4B. Regarding current trading prices, EDEMY is priced at $40.00, while TUIFF trades at $7.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 7.63, whereas TUIFF's P/E ratio is 5.17. In terms of profitability, EDEMY's ROE is +0.21%, compared to TUIFF's ROE of +0.52%. Regarding short-term risk, EDEMY is more volatile compared to TUIFF. This indicates potentially higher risk in terms of short-term price fluctuations for EDEMY.Check TUIFF's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 423.2M. In comparison, DRTGF has a market cap of 3.1B. Regarding current trading prices, EDEMY is priced at $40.00, while DRTGF trades at $17.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 7.63, whereas DRTGF's P/E ratio is 5.40. In terms of profitability, EDEMY's ROE is +0.21%, compared to DRTGF's ROE of +0.25%. Regarding short-term risk, EDEMY is less volatile compared to DRTGF. This indicates potentially lower risk in terms of short-term price fluctuations for EDEMY.Check DRTGF's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 423.2M. In comparison, LGDDF has a market cap of 2.9B. Regarding current trading prices, EDEMY is priced at $40.00, while LGDDF trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 7.63, whereas LGDDF's P/E ratio is 11.55. In terms of profitability, EDEMY's ROE is +0.21%, compared to LGDDF's ROE of +0.25%. Regarding short-term risk, EDEMY is more volatile compared to LGDDF. This indicates potentially higher risk in terms of short-term price fluctuations for EDEMY.Check LGDDF's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 423.2M. In comparison, FGETF has a market cap of 1.4B. Regarding current trading prices, EDEMY is priced at $40.00, while FGETF trades at $7.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 7.63, whereas FGETF's P/E ratio is 19.51. In terms of profitability, EDEMY's ROE is +0.21%, compared to FGETF's ROE of +0.09%. Regarding short-term risk, EDEMY is less volatile compared to FGETF. This indicates potentially lower risk in terms of short-term price fluctuations for EDEMY.Check FGETF's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 423.2M. In comparison, CTMLF has a market cap of 1.3B. Regarding current trading prices, EDEMY is priced at $40.00, while CTMLF trades at $9.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 7.63, whereas CTMLF's P/E ratio is 31.66. In terms of profitability, EDEMY's ROE is +0.21%, compared to CTMLF's ROE of +0.07%. Regarding short-term risk, EDEMY is less volatile compared to CTMLF. This indicates potentially lower risk in terms of short-term price fluctuations for EDEMY.Check CTMLF's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 423.2M. In comparison, TNLIY has a market cap of 1.1B. Regarding current trading prices, EDEMY is priced at $40.00, while TNLIY trades at $5.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 7.63, whereas TNLIY's P/E ratio is 11.51. In terms of profitability, EDEMY's ROE is +0.21%, compared to TNLIY's ROE of +0.35%. Regarding short-term risk, EDEMY is more volatile compared to TNLIY. This indicates potentially higher risk in terms of short-term price fluctuations for EDEMY.Check TNLIY's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 423.2M. In comparison, WEJTY has a market cap of 1.1B. Regarding current trading prices, EDEMY is priced at $40.00, while WEJTY trades at $3.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 7.63, whereas WEJTY's P/E ratio is 305.00. In terms of profitability, EDEMY's ROE is +0.21%, compared to WEJTY's ROE of +0.01%. Regarding short-term risk, EDEMY is more volatile compared to WEJTY. This indicates potentially higher risk in terms of short-term price fluctuations for EDEMY.Check WEJTY's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 423.2M. In comparison, EDDRF has a market cap of 532.1M. Regarding current trading prices, EDEMY is priced at $40.00, while EDDRF trades at $5.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 7.63, whereas EDDRF's P/E ratio is 9.67. In terms of profitability, EDEMY's ROE is +0.21%, compared to EDDRF's ROE of +0.21%. Regarding short-term risk, EDEMY is more volatile compared to EDDRF. This indicates potentially higher risk in terms of short-term price fluctuations for EDEMY.Check EDDRF's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 423.2M. In comparison, WEBJF has a market cap of 336.6M. Regarding current trading prices, EDEMY is priced at $40.00, while WEBJF trades at $0.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 7.63, whereas WEBJF's P/E ratio is 9.30. In terms of profitability, EDEMY's ROE is +0.21%, compared to WEBJF's ROE of +0.02%. Regarding short-term risk, EDEMY is less volatile compared to WEBJF. This indicates potentially lower risk in terms of short-term price fluctuations for EDEMY.Check WEBJF's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 423.2M. In comparison, OOBHF has a market cap of 327.6M. Regarding current trading prices, EDEMY is priced at $40.00, while OOBHF trades at $2.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 7.63, whereas OOBHF's P/E ratio is 15.07. In terms of profitability, EDEMY's ROE is +0.21%, compared to OOBHF's ROE of +0.02%. Regarding short-term risk, EDEMY is less volatile compared to OOBHF. This indicates potentially lower risk in terms of short-term price fluctuations for EDEMY.Check OOBHF's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 423.2M. In comparison, EOVBF has a market cap of 296M. Regarding current trading prices, EDEMY is priced at $40.00, while EOVBF trades at $13.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 7.63, whereas EOVBF's P/E ratio is -3.19. In terms of profitability, EDEMY's ROE is +0.21%, compared to EOVBF's ROE of +0.11%. Regarding short-term risk, EDEMY is less volatile compared to EOVBF. This indicates potentially lower risk in terms of short-term price fluctuations for EDEMY.Check EOVBF's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 423.2M. In comparison, LSMNF has a market cap of 211.3M. Regarding current trading prices, EDEMY is priced at $40.00, while LSMNF trades at $19.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 7.63, whereas LSMNF's P/E ratio is 13.55. In terms of profitability, EDEMY's ROE is +0.21%, compared to LSMNF's ROE of +0.21%. Regarding short-term risk, EDEMY is less volatile compared to LSMNF. This indicates potentially lower risk in terms of short-term price fluctuations for EDEMY.Check LSMNF's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 423.2M. In comparison, HSWLF has a market cap of 154.8M. Regarding current trading prices, EDEMY is priced at $40.00, while HSWLF trades at $1.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 7.63, whereas HSWLF's P/E ratio is 20.83. In terms of profitability, EDEMY's ROE is +0.21%, compared to HSWLF's ROE of +0.10%. Regarding short-term risk, EDEMY is more volatile compared to HSWLF. This indicates potentially higher risk in terms of short-term price fluctuations for EDEMY.Check HSWLF's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 423.2M. In comparison, HWGG has a market cap of 101.1M. Regarding current trading prices, EDEMY is priced at $40.00, while HWGG trades at $4.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 7.63, whereas HWGG's P/E ratio is -410.00. In terms of profitability, EDEMY's ROE is +0.21%, compared to HWGG's ROE of -2.20%. Regarding short-term risk, EDEMY is less volatile compared to HWGG. This indicates potentially lower risk in terms of short-term price fluctuations for EDEMY.Check HWGG's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 423.2M. In comparison, TRZBF has a market cap of 83.2M. Regarding current trading prices, EDEMY is priced at $40.00, while TRZBF trades at $1.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 7.63, whereas TRZBF's P/E ratio is 0.35. In terms of profitability, EDEMY's ROE is +0.21%, compared to TRZBF's ROE of -0.48%. Regarding short-term risk, EDEMY is more volatile compared to TRZBF. This indicates potentially higher risk in terms of short-term price fluctuations for EDEMY.Check TRZBF's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 423.2M. In comparison, ONVC has a market cap of 30.8M. Regarding current trading prices, EDEMY is priced at $40.00, while ONVC trades at $2.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 7.63, whereas ONVC's P/E ratio is 21.00. In terms of profitability, EDEMY's ROE is +0.21%, compared to ONVC's ROE of +0.28%. Regarding short-term risk, EDEMY is more volatile compared to ONVC. This indicates potentially higher risk in terms of short-term price fluctuations for EDEMY.Check ONVC's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 423.2M. In comparison, ZMWYF has a market cap of 992.7K. Regarding current trading prices, EDEMY is priced at $40.00, while ZMWYF trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 7.63, whereas ZMWYF's P/E ratio is -0.63. In terms of profitability, EDEMY's ROE is +0.21%, compared to ZMWYF's ROE of +0.22%. Regarding short-term risk, EDEMY is more volatile compared to ZMWYF. This indicates potentially higher risk in terms of short-term price fluctuations for EDEMY.Check ZMWYF's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 423.2M. In comparison, NNAX has a market cap of 247.8K. Regarding current trading prices, EDEMY is priced at $40.00, while NNAX trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 7.63, whereas NNAX's P/E ratio is N/A. In terms of profitability, EDEMY's ROE is +0.21%, compared to NNAX's ROE of +0.07%. Regarding short-term risk, EDEMY is more volatile compared to NNAX. This indicates potentially higher risk in terms of short-term price fluctuations for EDEMY.Check NNAX's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 423.2M. In comparison, MONDQ has a market cap of 174.8K. Regarding current trading prices, EDEMY is priced at $40.00, while MONDQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 7.63, whereas MONDQ's P/E ratio is N/A. In terms of profitability, EDEMY's ROE is +0.21%, compared to MONDQ's ROE of -1.30%. Regarding short-term risk, EDEMY is less volatile compared to MONDQ. This indicates potentially lower risk in terms of short-term price fluctuations for EDEMY.Check MONDQ's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 423.2M. In comparison, CDNO has a market cap of 119.2K. Regarding current trading prices, EDEMY is priced at $40.00, while CDNO trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 7.63, whereas CDNO's P/E ratio is N/A. In terms of profitability, EDEMY's ROE is +0.21%, compared to CDNO's ROE of -1.07%. Regarding short-term risk, EDEMY is less volatile compared to CDNO. This indicates potentially lower risk in terms of short-term price fluctuations for EDEMY.Check CDNO's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 423.2M. In comparison, WESC has a market cap of 13K. Regarding current trading prices, EDEMY is priced at $40.00, while WESC trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 7.63, whereas WESC's P/E ratio is N/A. In terms of profitability, EDEMY's ROE is +0.21%, compared to WESC's ROE of +1.30%. Regarding short-term risk, EDEMY is more volatile compared to WESC. This indicates potentially higher risk in terms of short-term price fluctuations for EDEMY.Check WESC's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 423.2M. In comparison, ARMV has a market cap of 2.4K. Regarding current trading prices, EDEMY is priced at $40.00, while ARMV trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 7.63, whereas ARMV's P/E ratio is -0.01. In terms of profitability, EDEMY's ROE is +0.21%, compared to ARMV's ROE of +0.26%. Regarding short-term risk, EDEMY is less volatile compared to ARMV. This indicates potentially lower risk in terms of short-term price fluctuations for EDEMY.Check ARMV's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 423.2M. In comparison, GWYT has a market cap of 1.8K. Regarding current trading prices, EDEMY is priced at $40.00, while GWYT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 7.63, whereas GWYT's P/E ratio is N/A. In terms of profitability, EDEMY's ROE is +0.21%, compared to GWYT's ROE of +0.37%. Regarding short-term risk, EDEMY is less volatile compared to GWYT. This indicates potentially lower risk in terms of short-term price fluctuations for EDEMY.Check GWYT's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 423.2M. In comparison, OHTR has a market cap of 0. Regarding current trading prices, EDEMY is priced at $40.00, while OHTR trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 7.63, whereas OHTR's P/E ratio is N/A. In terms of profitability, EDEMY's ROE is +0.21%, compared to OHTR's ROE of N/A. Regarding short-term risk, EDEMY is less volatile compared to OHTR. This indicates potentially lower risk in terms of short-term price fluctuations for EDEMY.Check OHTR's competition here